Free Trial

NuCana (NCNA) Competitors

NuCana logo
$0.06 0.00 (-1.00%)
Closing price 04:00 PM Eastern
Extended Trading
$0.06 0.00 (-2.01%)
As of 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NCNA vs. CWBR, EVFM, NMTR, ATXI, PTPI, TRVN, HEPA, PBLA, SYRS, and SRNE

Should you be buying NuCana stock or one of its competitors? The main competitors of NuCana include CohBar (CWBR), Evofem Biosciences (EVFM), 9 Meters Biopharma (NMTR), Avenue Therapeutics (ATXI), Petros Pharmaceuticals (PTPI), Trevena (TRVN), Hepion Pharmaceuticals (HEPA), Panbela Therapeutics (PBLA), Syros Pharmaceuticals (SYRS), and Sorrento Therapeutics (SRNE). These companies are all part of the "pharmaceutical products" industry.

NuCana vs. Its Competitors

CohBar (NASDAQ:CWBR) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

In the previous week, NuCana had 1 more articles in the media than CohBar. MarketBeat recorded 1 mentions for NuCana and 0 mentions for CohBar. CohBar's average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score.

Company Overall Sentiment
CohBar Neutral
NuCana Neutral

CohBar has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, NuCana has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

NuCana has a consensus price target of $25.00, suggesting a potential upside of 41,776.05%. Given NuCana's stronger consensus rating and higher possible upside, analysts plainly believe NuCana is more favorable than CohBar.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CohBar
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NuCana
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CohBarN/AN/A-$12.18MN/AN/A
NuCanaN/AN/A-$24.28M-$7.02-0.01

CohBar's return on equity of 0.00% beat NuCana's return on equity.

Company Net Margins Return on Equity Return on Assets
CohBarN/A N/A N/A
NuCana N/A -319.85%-88.55%

2.5% of CohBar shares are held by institutional investors. Comparatively, 44.0% of NuCana shares are held by institutional investors. 6.5% of CohBar shares are held by insiders. Comparatively, 31.2% of NuCana shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

NuCana beats CohBar on 7 of the 10 factors compared between the two stocks.

Get NuCana News Delivered to You Automatically

Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NCNA vs. The Competition

MetricNuCanaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$363K$2.96B$5.57B$9.02B
Dividend YieldN/A2.44%5.25%4.03%
P/E Ratio-0.0121.1127.2020.15
Price / SalesN/A260.29419.15184.83
Price / CashN/A41.8337.0657.97
Price / Book0.047.748.085.60
Net Income-$24.28M-$54.96M$3.16B$248.50M
7 Day PerformanceN/A6.04%3.77%5.15%
1 Month PerformanceN/A4.47%3.91%7.62%
1 Year PerformanceN/A6.12%34.22%21.56%

NuCana Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NCNA
NuCana
2.5237 of 5 stars
$0.06
-1.0%
$25.00
+41,776.0%
-98.0%$363KN/A-0.0130Gap Up
High Trading Volume
CWBR
CohBar
N/A$0.41
flat
N/AN/A$1.19MN/A0.0010
EVFM
Evofem Biosciences
0.6059 of 5 stars
$0.01
-1.0%
N/A-6.5%$1.18M$11.39M-0.02120Gap Up
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/A-0.0220
ATXI
Avenue Therapeutics
2.1667 of 5 stars
$0.32
-6.2%
N/A-93.0%$1.02MN/A0.024Trending News
PTPI
Petros Pharmaceuticals
0.6597 of 5 stars
$0.03
-8.9%
N/A-99.7%$991K$5.11M-0.0120Gap Down
TRVN
Trevena
2.4599 of 5 stars
$0.91
-3.2%
$5.00
+449.5%
-82.0%$873K$443K-0.0240Gap Down
HEPA
Hepion Pharmaceuticals
0.3248 of 5 stars
$0.07
+6.7%
N/A-99.9%$787KN/A-0.0220Gap Up
PBLA
Panbela Therapeutics
0.0956 of 5 stars
$0.16
-1.5%
N/A-57.0%$765KN/A0.006
SYRS
Syros Pharmaceuticals
4.3542 of 5 stars
$0.03
+11.6%
$3.33
+11,804.8%
-100.0%$751K$386K-0.01120
SRNE
Sorrento Therapeutics
0.7075 of 5 stars
$0.00
-7.1%
N/A-88.8%$717K$60.32M0.00800Gap Down

Related Companies and Tools


This page (NASDAQ:NCNA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners